NATALEE is a global phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali (ribociclib) with ET as an investigational adjuvant treatment versus ET alone in ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast ... Last month, Novartis released new data from the ALITHIOS open-label extension study.

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Registered voters in Washington began casting their ballots Friday for the upcoming General Election as drop boxes officially opened on Oct. 18. Ballots must be mailed by each county to voters by ...

Authorities in Portland, Oregon, and Vancouver, Washington, said they've opened investigations after two ballot boxes went up in flames early Monday morning. In Portland, an incendiary device was ...